Active	Status	Sponsor type	Region	Phase	Filter
44 Active 10 Inactive 54 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

35 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Levy, Cynthia
NCT04950127 / 2021-000007-21: Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)	Active, not recruiting	3	238	Europe, Canada, Japan, US, RoW	Linerixibat, Placebo	GlaxoSmithKline	Pruritus	10/24	01/25
LLSAT, NCT04167358 / 2019-003158-10: Linerixibat Long-term Safety, and Tolerability Study	Recruiting	3	251	Europe, Canada, Japan, US, RoW	Linerixibat	GlaxoSmithKline, GlaxoSmithKline LLC, GlaxoSmithKline Research & Development Limited	Cholestasis	02/27	02/27
NCT05883748: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants with EPP	Enrolling by invitation	2/3	200	US, RoW	DISC-1459, Bitopertin, RO4917838	Disc Medicine, Inc	Erythropoietic Protoporphyria	06/28	06/28
NCT05308472: Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants with EPP	Completed	2	75	US	DISC-1459, Bitopertin, RO4917838, Placebo	Disc Medicine, Inc	Erythropoietic Protoporphyria	02/24	08/24
PACIFIC, NCT05525520 / 2021-002526-25: Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis	Completed	2	62	Europe, Canada, US, RoW	EP547, Placebo	Escient Pharmaceuticals, Inc, Escient Pharmaceuticals, Inc.	Pruritus	07/24	09/24
NCT05239468 / 2022-001241-20: Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC	Active, not recruiting	2	60	US	Bezafibrate 100 mg, Bezafibrate 200 mg, Obeticholic Acid 5 mg, Obeticholic Acid placebo, Bezafibrate Placebo	Intercept Pharmaceuticals, Intercept Pharmaceuticals, Inc.	Primary Biliary Cholangitis	11/24	02/25
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)	Recruiting	2	200	Europe, Canada, US, RoW	Volixibat, SHP626, Placebo	Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.	Primary Sclerosing Cholangitis	09/25	12/25
NCT04884815 / 2020-005266-34: Study of UX701 Gene Transfer for the Treatment of Wilson Disease	Active, not recruiting	1/2	78	Europe, Canada, US	UX701, Placebo	Ultragenyx Pharmaceutical Inc, Ultragenyx Pharmaceutical Inc.	Wilson Disease	08/26	11/31
Hassanein, Tarek
NCT01846663: Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy	Terminated	4	6	US	Placebo, Rifaximin, XIFAXAN® Tablets	Bausch Health Americas, Inc.	Hepatic Encephalopathy	02/16	02/16
PRECIOSA, NCT03451292 / 2016-001789-28: Effects of Long-Term Administration of Human Albumin in Subjects With Decompensated Cirrhosis and Ascites	Completed	3	410	Europe, Canada, US, RoW	Albutein 20% Injectable Solution, Standard medical treatment	Grifols Therapeutics LLC, Instituto Grifols, S.A.	Decompensated Cirrhosis and Ascites	05/24	05/24
APACHE, NCT03702920 / 2016-001787-10: Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%	Recruiting	3	380	Europe, US	SMT + PE-A 5%, Albutein 5%, Standard Medical Treatment, SMT	Grifols Therapeutics LLC, Instituto Grifols, S.A.	Acute-On-Chronic Liver Failure	10/26	10/26
ARGON-2, NCT04378010 / 2019-003876-38: A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH	Terminated	2b	98	Europe, Canada, US, RoW	EDP-305 1.5 mg, EDP-305, EDP-305 2 mg, Placebo	Enanta Pharmaceuticals, Inc, Enanta Pharmaceuticals, Inc.	Non-Alcoholic Steatohepatitis	10/21	11/21
NAVIGATE, NCT04365868 / 2019-001983-31: Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis	Active, not recruiting	2b	357	Europe, Canada, US, RoW	belapectin, GR-MD-02, galactoarabino rhamnogalacturonate, Placebo	Galectin Therapeutics Inc., Galectin Therapeutics Inc	Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis	12/24	12/24
PACIFIC, NCT05525520 / 2021-002526-25: Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis	Completed	2	62	Europe, Canada, US, RoW	EP547, Placebo	Escient Pharmaceuticals, Inc, Escient Pharmaceuticals, Inc.	Pruritus	07/24	09/24
NCT05239468 / 2022-001241-20: Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC	Active, not recruiting	2	60	US	Bezafibrate 100 mg, Bezafibrate 200 mg, Obeticholic Acid 5 mg, Obeticholic Acid placebo, Bezafibrate Placebo	Intercept Pharmaceuticals, Intercept Pharmaceuticals, Inc.	Primary Biliary Cholangitis	11/24	02/25
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)	Recruiting	2	200	Europe, Canada, US, RoW	Volixibat, SHP626, Placebo	Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.	Primary Sclerosing Cholangitis	09/25	12/25
NCT06598943: A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis	Recruiting	2	140	Europe, Japan, US, RoW	Eltrekibart, LY3041658, Mirikizumab, LY3074828, Placebo	Eli Lilly and Company	Ulcerative Colitis, Ulcerative Colitis Chronic	12/27	09/28
NCT05104853: Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects with Primary Biliary Cholangitis	Active, not recruiting	1/2	42	US	CNP-104, Placebo	COUR Pharmaceutical Development Company, Inc.	Primary Biliary Cholangitis	01/26	01/26
NCT05490888: Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics	Recruiting	1	62	US	PHIN-214 Subcutaneous injection, Terlipressin derivative	PharmaIN	Cirrhosis, Liver, Liver Fibrosis, Ascites Hepatic	10/25	12/25
Forman, Lisa
NCT01846663: Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy	Terminated	4	6	US	Placebo, Rifaximin, XIFAXAN® Tablets	Bausch Health Americas, Inc.	Hepatic Encephalopathy	02/16	02/16
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)	Recruiting	2	200	Europe, Canada, US, RoW	Volixibat, SHP626, Placebo	Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.	Primary Sclerosing Cholangitis	09/25	12/25
NCT05569759: A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)	Active, not recruiting	2	24	US	zetomipzomib, KZR-616, placebo, sterile water for injection, zetomipzomib in open-label extension	Kezar Life Sciences, Inc.	Autoimmune Hepatitis	02/25	08/25
NCT06699121: A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC	Not yet recruiting	2	87	US	LB-P8 low-dose, LB-P8 high-dose, Placebo	LISCure Biosciences	Primary Sclerosing Cholangitis (PSC)	03/28	02/29
Nguyen, Laura
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)	Recruiting	2	200	Europe, Canada, US, RoW	Volixibat, SHP626, Placebo	Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.	Primary Sclerosing Cholangitis	09/25	12/25
NCT05512026: Performance of the Poseidon System for Fluid Management During Water-aided Colonoscopy	Not yet recruiting	N/A	30	US	Feasibility Assessment	WAE Medical	Colonic Disease	01/23	03/23
Dae, Katheryn
D-LIVR, NCT03719313 / 2018-003167-54: Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a	Completed	3	407	Europe, Canada, US, RoW	Lonafarnib, EBP994, Sarasar, LNF, Ritonavir, Norvir, RTV, PEG IFN-alfa-2a, Pegasys, pegylated interferon-alfa, Placebo Lonafarnib, Placebo Ritonavir	Eiger BioPharmaceuticals	Hepatitis Delta Virus	10/22	03/23
NCT05239468 / 2022-001241-20: Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC	Active, not recruiting	2	60	US	Bezafibrate 100 mg, Bezafibrate 200 mg, Obeticholic Acid 5 mg, Obeticholic Acid placebo, Bezafibrate Placebo	Intercept Pharmaceuticals, Intercept Pharmaceuticals, Inc.	Primary Biliary Cholangitis	11/24	02/25
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)	Recruiting	2	200	Europe, Canada, US, RoW	Volixibat, SHP626, Placebo	Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.	Primary Sclerosing Cholangitis	09/25	12/25
Yimam, Kidist
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)	Recruiting	2	200	Europe, Canada, US, RoW	Volixibat, SHP626, Placebo	Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.	Primary Sclerosing Cholangitis	09/25	12/25
NCT05569759: A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)	Active, not recruiting	2	24	US	zetomipzomib, KZR-616, placebo, sterile water for injection, zetomipzomib in open-label extension	Kezar Life Sciences, Inc.	Autoimmune Hepatitis	02/25	08/25
Thornton, Mary
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)	Recruiting	2	200	Europe, Canada, US, RoW	Volixibat, SHP626, Placebo	Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.	Primary Sclerosing Cholangitis	09/25	12/25
MoveS-it, NCT04602390: Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis	Completed	1	33	US	ANK-700, Placebo	Anokion SA	Multiple Sclerosis (MS), Relapsing Remitting Multiple Sclerosis	04/24	04/24
Herrera, Edisson Aguilera
SPARKLE, NCT04119843 / 2019-001599-12: Safety and Diagnostic Efficacy of Mangoral in Participants With Focal Liver Lesions and Reduced Kidney Function	Completed	3	87	Europe, US, RoW	Mangoral, Orviglance, CMC-001, ACE-MBCA	Ascelia Pharma AB	Known or Suspected Focal Liver Lesions, Severe Renal Impairment	02/23	02/23
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)	Recruiting	2	200	Europe, Canada, US, RoW	Volixibat, SHP626, Placebo	Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.	Primary Sclerosing Cholangitis	09/25	12/25
Padila, Felisa Carmen
PACIFIC, NCT05525520 / 2021-002526-25: Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis	Completed	2	62	Europe, Canada, US, RoW	EP547, Placebo	Escient Pharmaceuticals, Inc, Escient Pharmaceuticals, Inc.	Pruritus	07/24	09/24